Kenneth Rainin Foundation Awards Over $2 Million For Collaborative IBD Research Projects
February 04, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation announced that it has awarded over $2 million in grants through its Synergy Awards program. This program encourages...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
November 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.; Nash Pharmaceuticals Inc.
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)...
Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
November 07, 2018 09:42 ET
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
Kenneth Rainin Foundation Awards $2.6 Million for Cutting-Edge IBD Research
October 02, 2018 08:00 ET
|
Kenneth Rainin Foundation
Oakland, California, Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.6 million through its Innovator Awards program to improve the prediction and prevention of...
Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
October 01, 2018 07:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
August 02, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
July 26, 2018 09:00 ET
|
Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...
Lyfebulb and UnitedHealth Group Announce 11 Finalists for Their 2018 Innovation Challenge for Patient Entrepreneurs
June 28, 2018 09:00 ET
|
Lyfebulb
Challenge recognizes companies whose founders have been affected by inflammatory bowel disease Winners to receive monetary prizes for creative and effective solutions to address IBD MINNETONKA,...
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...